MN HF2624

Expands Minnesota's prescription monitoring program from "controlled substances" to "reportable substances," adding FDA-approved opioid antagonists (overdose reversal agents like naloxone) to the list of tracked medications alongside existing controlled substances, butalbital, and gabapentin

Restricts access to opioid antagonist dispensing data exclusively to Board of Pharmacy personnel and authorized contractors engaged in program administration, preventing prescribers, dispensers, and law enforcement from viewing this information

Requires dispensers to report all reportable substance prescriptions to the Board of Pharmacy's electronic database, including prescriber and patient information, drug details, quantities, and days supply

Maintains existing prescriber requirements to check the database before issuing initial Schedule II-IV opiate prescriptions and every three months for chronic pain or opioid addiction treatment patients

Preserves patient privacy protections, data retention limits (12 months for most users), and prohibitions on using the database to initiate disciplinary actions against prescribers without a warrant or court order